GlobeNewswire: Histogenics Corporation Contains the last 10 of 104 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:51:28ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/09/26/1921591/0/en/Histogenics-Corporation-Announces-Approval-of-Merger-by-Stockholders-at-Special-Meeting.html?f=22&fvtc=4&fvtv=24287Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting2019-09-26T20:25:00Z<![CDATA[BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen, Inc. (“Ocugen”) were approved by Histogenics’ stockholders at a special meeting held on September 26, 2019. As previously announced, the proposed merger will create a public company under which the stockholders of Ocugen will become majority holders of the combined company.]]>https://www.globenewswire.com/news-release/2019/09/12/1914858/0/en/Histogenics-Corporation-Announces-Adjournment-of-its-Special-Meeting-to-Thursday-September-26-2019.html?f=22&fvtc=4&fvtv=24287Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 20192019-09-12T13:15:00Z<![CDATA[BOSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the “Special Meeting”) held on September 12, 2019, at 9:00 a.m., local time, until Thursday, September 26, 2019 at 9:00 a.m., local time, at which time Histogenics’ stockholders will vote on the proposals to be considered at the Special Meeting (subject to any potential additional adjournments), including a proposals necessary to approve Histogenics’ proposed merger with Ocugen, Inc. (“Ocugen”) as described in the definitive prospectus/proxy statement/information statement, which is included as part of Histogenics’ Registration Statement on Form S-4, as amended (File No. 333-232147). The Special Meeting will still be held at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP located at One Marina Park Drive, Suite 900, Boston, MA 02210. The Special Meeting was adjourned in order to solicit additional proxies for the proposals to be presented at the Special Meeting.]]>https://www.globenewswire.com/news-release/2019/09/11/1914408/0/en/Histogenics-Corporation-Announces-Intent-to-Convene-and-Adjourn-Its-Special-Meeting.html?f=22&fvtc=4&fvtv=24287Histogenics Corporation Announces Intent to Convene and Adjourn Its Special Meeting2019-09-11T20:05:00Z<![CDATA[BOSTON, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting any business, its special meeting of stockholders (the “Special Meeting”) to be held with respect to its proposed merger with Ocugen, Inc. (“Ocugen”) pursuant to the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, as amended (the “Merger Agreement”), by and among the Company, its wholly-owned subsidiary, Restore Merger Sub, Inc. (“Merger Sub”) and Ocugen, which provides for the merger (the “Merger”) of Merger Sub with and into Ocugen. The Special Meeting is being adjourned in order to solicit additional proxies for the proposals to be presented at the Special Meeting.]]>https://www.globenewswire.com/news-release/2019/04/08/1798875/0/en/Histogenics-and-Ocugen-Enter-into-Definitive-Merger-Agreement-to-Create-Nasdaq-Listed-Clinical-Stage-Company-Developing-Novel-Ocular-Gene-Therapies-and-Biotherapeutics.html?f=22&fvtc=4&fvtv=24287Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics2019-04-08T11:00:00Z<![CDATA[— Conference call to be held today at 8:30 a.m. Eastern Time — — Conference call to be held today at 8:30 a.m. Eastern Time —]]>https://www.globenewswire.com/news-release/2018/12/21/1677926/0/en/Histogenics-and-FDA-Conclude-Discussions-Regarding-NeoCart-Phase-3-Clinical-Trial-Data-and-Regulatory-Pathway.html?f=22&fvtc=4&fvtv=24287Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway2018-12-21T21:05:00Z<![CDATA[‒ Histogenics to Discontinue Development of NeoCart and Explore Strategic Alternatives ‒ ‒ Histogenics to Discontinue Development of NeoCart and Explore Strategic Alternatives ‒]]>https://www.globenewswire.com/news-release/2018/11/29/1658951/0/en/Histogenics-and-FDA-Continue-to-Discuss-NeoCart-Phase-3-Clinical-Trial-Data-and-Potential-Regulatory-Pathway.html?f=22&fvtc=4&fvtv=24287Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway2018-11-29T13:30:00Z<![CDATA[WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on its ongoing dialogue with the U.S. Food and Drug Administration (the FDA). Since the initial Type C meeting in October 2018, Histogenics and the FDA have continued their discussions on the clinical data generated to date, the potential need for any additional supplemental clinical data (which may include longer-term data from the ongoing Phase 3 trial or additional studies) and potential alternative regulatory pathways for the NeoCart Biologics License Application (BLA). The FDA has not yet made a final decision regarding a potential BLA submission. Histogenics intends to provide a further update by the end of 2018 or early 2019 based on additional feedback from the FDA, once available.]]>https://www.globenewswire.com/news-release/2018/11/08/1647759/0/en/Histogenics-Corporation-Announces-Third-Quarter-2018-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=24287Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results2018-11-08T11:30:00Z<![CDATA[WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to Provide Funding Into Middle of 2019 ‒‒ Histogenics to Host Conference Call and Webcast Today at 8:30 a.m. ET ‒]]>https://www.globenewswire.com/news-release/2018/11/01/1641629/0/en/Histogenics-and-FDA-to-Continue-Discussions-on-NeoCart-Phase-3-Clinical-Trial-Data-and-Potential-Regulatory-Pathway.html?f=22&fvtc=4&fvtv=24287Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway2018-11-01T20:05:00Z<![CDATA[WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on preliminary feedback from the Type C meeting held with the U.S. Food and Drug Administration (the FDA) on October 30, 2018. At the meeting, the top-line results from the NeoCart Phase 3 clinical trial and the potential for the submission of a Biologics License Application (BLA) were discussed. Following the meeting, the FDA and Histogenics continue to discuss the clinical data generated to date, the potential need for any additional supplemental clinical data (which may include longer-term data from the ongoing Phase 3 trial or additional studies) and potential alternative regulatory pathways for the BLA to be accepted. The FDA has not made a final decision regarding a potential BLA submission and based on expected feedback from the FDA, Histogenics intends to provide a further update on these negotiations by the end of November 2018.]]>https://www.globenewswire.com/news-release/2018/10/25/1627509/0/en/Histogenics-Corporation-to-Report-Third-Quarter-2018-Financial-Results-on-November-8-2018.html?f=22&fvtc=4&fvtv=24287Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 20182018-10-25T20:15:00Z<![CDATA[WALTHAM, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its third quarter 2018 financial results on November 8, 2018, before the U.S. financial markets open.]]>https://www.globenewswire.com/news-release/2018/10/10/1619579/0/en/Histogenics-Corporation-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=24287Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants2018-10-10T20:01:00Z<![CDATA[WALTHAM, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The net proceeds to Histogenics from this offering are approximately $15.4 million, after deducting underwriting discounts and commissions, and estimated offering expenses payable by Histogenics.]]>